Early clinical trials for breast cancer prevention demonstrated that 6 months of letrozole treatment in postmenopausal women taking hormone replacement therapies could reduce Ki-67 proliferation markers, prompting further studies (90). The gene discussed is MKI67; the disease is breast carcinoma.